Wyeth Aims For Two NME Launches A Year Under Retooled R&D Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes to the R&D process include refocusing efforts on discovery of new molecular entities, with a reduced emphasis on line extensions. Only 23% of Wyeth’s portfolio is made up of line extensions versus 45% in 2001. Wyeth is also beginning to link scientist compensation to R&D goals.